Acro Biomedical (ACBM) Revenue (2017 - 2022)

Acro Biomedical has reported Revenue for 6 years, with the latest figure at $360000.0 in Q4 2022.

• For the quarter ending Q4 2022, Revenue fell 39.8% year-over-year to $360000.0; the trailing twelve-month figure through Sep 2023 stood at $360000.0 (down 59.84% YoY), and the FY2022 full-year result was $658500.0, down 45.01% from the prior year.
• Revenue for Q4 2022 stood at $360000.0, up from $298500.0 in the prior quarter.
• The five-year high for Revenue was $2.4 million in Q3 2018, with the low at $99500.0 in Q1 2021.
• Average Revenue over 5 years is $969181.8, with a median of $598000.0 recorded in 2021.
• Year-over-year, Revenue plunged 85.71% in 2019 and jumped 200.0% in 2022.
• Tracing ACBM's Revenue over 5 years: stood at $1.4 million in 2018, then sank by 85.71% to $193536.0 in 2019, then jumped by 255.47% to $687964.0 in 2020, then dropped by 13.08% to $598000.0 in 2021, then slumped by 39.8% to $360000.0 in 2022.
• The last three Revenue figures came in at $360000.0 (Q4 2022), $298500.0 (Q1 2022), and $598000.0 (Q4 2021), per Business Quant data.

Peer Comparison